Increasing Incidence of Chronic Graft-versus-Host Disease inAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 2, 2015, Pages 266-274

  Arai, Sally ^a   Arora, Mukta ^b   Wang, Tao ^c   Spellman, Stephen R ^d   He, Wensheng ^c   Couriel, Daniel R ^e   Urbano Ispizua, Alvaro ^f   Cutler, Corey S ^g   Bacigalupo, Andrea A ^h   Battiwalla, Minoo ⁱ   Flowers, Mary E ^j   Juckett, Mark B ^k   Lee, Stephanie J ^j   Loren, Alison W ^l   Klumpp, Thomas R ^m   Prockup, Susan E ⁿ   Ringdén, Olle T H ^o   Savani, Bipin N ^p   Socié, Gérard ^q   Schultz, Kirk R ^r   Spitzer, Thomas ^s   Teshima, Takanori ^t   Bredeson, Christopher N ^u   Jacobsohn, David A ^v   Hayashi, Robert J ^w   Drobyski, William R ^c   Frangoul, Haydar A ^x   Akpek, Görgün ^y   Ho, Vincent T ^g   Lewis, Victor A ^z   Gale, Robert Peter ^aa   Koreth, John ^g   Chao, Nelson J ^ab   Aljurf, Mahmoud D ^ac   Cooper, Brenda W ^ad   Laughlin, Mary J ^ae   Hsu, Jack W ^af   Hematti, Peiman ^k   Verdonck, Leo F ^ag   Solh, Melhelm M ^ah   Norkin, Maxim ^af   Reddy, Vijay ^ai   Martino, Rodrigo ^aj   Gadalla, Shahinaz ^ak   Goldberg, Jenna D ⁿ   McCarthy, Philip L ^al   Pérez Simón, José A ^am   Khera, Nandita ^an   Lewis, Ian D ^ao   Atsuta, Yoshiko ^ap,aq   Olsson, Richard F ^ar,as   Saber, Wael ^c   Waller, Edmund K ^at   Blaise, Didier ^au   Pidala, Joseph A ^av   Martin, Paul J ^j   Satwani, Prakash ^aw   Bornhäuser, Martin ^ax   Inamoto, Yoshihiro ^j   Weisdorf, Daniel J ^b   Horowitz, Mary M ^c   Pavletic, Steven Z ^ak   more..

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NATIONAL MARROW DONOR PROGRAM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f HOSPITAL CLÍNIC   (Spain)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k University of Wisconsin Health   (United States)

^l HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^m TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^q SAINT LOUIS HOSPITAL   (France)

^r UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

^t KYUSHU UNIVERSITY HOSPITAL   (Japan)

^u UNIVERSITY OF OTTAWA   (Canada)

^v CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^w WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y USA   (United States)

^z ALBERTA CHILDREN'S HOSPITAL   (Canada)

^aa IMPERIAL COLLEGE LONDON   (United Kingdom)

^ab DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ac KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^ad UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^ae Cleveland Cord Blood Center   (United States)

^af UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^ag ISALA HOSPITAL   (Netherlands)

^ah FLORIDA HOSPITAL   (United States)

^ai UNIVERSITY OF FLORIDA   (United States)

^aj HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^ak NATIONAL CANCER INSTITUTE   (United States)

^al ROSWELL PARK CANCER INSTITUTE   (United States)

^am Instituto de Biomedicina de Sevilla   (Spain)

^an MAYO CLINIC   (United States)

^ao ROYAL ADELAIDE HOSPITAL   (Australia)

^ap JAPANESE DATA CENTER FOR HEMATOPOIETIC CELL TRANSPLANTATION   (Japan)

^aq NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ar KAROLINSKA INSTITUTE   (Sweden)

^as UPPSALA UNIVERSITY   (Sweden)

^at EMORY UNIVERSITY   (United States)

^au INSTITUT PAOLI CALMETTES   (France)

^av H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^aw New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^ax UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

Allogeneic transplant; CGVHD; Incidence; Nonrelapse mortality

Indexed keywords

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; NEWBORN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK FACTOR; YOUNG ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL;

MYELOABLATIVE AGENT;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; INTERNATIONAL COOPERATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84920903701     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.021     Document Type: Article

References (32)

1. Socie G., Stone J.V., Wingard J.R., et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. NEngl J Med 1999, 341:14-21.
2. Lee S.J., Vogelsang G., Flowers M. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
3. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
4. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
5. Ringden O., Paulin T., Lonnqvist B., Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol 1985, 13:1062-1067.
6. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104:3501-3506.
7. Remberger M., Beelen D.W., Fauser A., et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005, 105:548-551.
8. Ringden O., Labopin M., Bacigalupo A., et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. JClin Oncol 2002, 20:4655-4664.
9. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
10. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
11. Weisdorf D., Zhang M.J., Arora M., et al. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012, 18:1727-1733.
12. Bar M., Sandmaier B.M., Inamoto Y., et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 2013, 19:949-957.
13. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
14. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
15. Lee S.J., Klein J.P., Barrett A.J., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100:406-414.
16. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
18. Klein J.P., Anderson P.K. Regression modeling of competing risks data based on pseudo values of the cumulative incidence function. Biometrics 2005, 61:223-229.
19. Arora M., Nagaraj S., Witte J., et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
20. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic cell transplantation. NEngl J Med 2010, 363:2091-2101.
21. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. JClin Oncol 2013, 31:2437-2449.
22. Remberger M., Ackefors M., Berglund S., et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years: a single-center study. Biol Blood Marrow Transplant 2011, 17:1688-1697.
23. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998, 22:755-761.
24. Luger S., Sacks N. Bone marrow transplantation for myelodysplastic syndrome-who? when? and which?. Bone Marrow Transplant 2002, 30:199-206.
25. Cutler C., Giri S., Jeyapalan S., et al. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: a meta-analysis. JClin Oncol 2001, 19:3685-3691.
26. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
27. Malladi R.K., Peniket A.J., Littlewood T.J., et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009, 43:709-715.
28. Devine S.M., Carter S., Soiffer R.J., et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biol Bood Marrow Transplant 2011, 17:1343-1351.
29. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
30. Couriel D.R., Saliba R.M., Giralt S., et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004, 10:178-185.
31. Subramaniam D.S., Fowler D.H., Pavletic S.Z. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia 2007, 21:853-859.
32. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.